Cellectar Biosciences, Inc. (CLRB): Price and Financial Metrics
CLRB Price/Volume Stats
| Current price | $3.03 | 52-week high | $4.45 |
| Prev. close | $3.04 | 52-week low | $1.33 |
| Day low | $3.01 | Volume | 806,854 |
| Day high | $3.16 | Avg. volume | 1,694,675 |
| 50-day MA | $3.66 | Dividend yield | N/A |
| 200-day MA | $2.75 | Market Cap | 97.75M |
CLRB Stock Price Chart Interactive Chart >
Cellectar Biosciences, Inc. (CLRB) Company Bio
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is based in Madison, Wisconsin.
Latest CLRB News From Around the Web
Below are the latest news stories about CELLECTAR BIOSCIENCES INC that investors may wish to consider to help them evaluate CLRB as an investment opportunity.
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research FoundationExclusive License Agreement to Develop and Commercialize Pediatric Cancer TreatmentsFLORHAM PARK, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a new licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research condu |
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC PlatformExpanded Global Patent Provides Protection for Phospholipid Drug Conjugate™ (PDC) Platform to Deliver Flavaglines as Targeted Anticancer PayloadsFLORHAM PARK, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that is has received Notice of Allowance for the patent titled, “Phospholipid-flavagline conjug |
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit EuropePresentation to Discuss Advancing Universal Targeted RadiotherapiesFLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar’s chief operating officer (COO), will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe, being he |
Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call TranscriptCellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead. Monique Kosse: Thank you, operator, […] |
CLRB Price Returns
| 1-mo | -18.77% |
| 3-mo | -12.93% |
| 6-mo | 15.21% |
| 1-year | 102.42% |
| 3-year | -77.88% |
| 5-year | -87.05% |
| YTD | 9.39% |
| 2023 | 61.99% |
| 2022 | -74.25% |
| 2021 | -68.08% |
| 2020 | -7.56% |
| 2019 | 45.16% |
Loading social stream, please wait...